Advisory board meetings are often used to address perceived knowledge gaps and build consensus. They serve to capture and distil the combined wisdom of a group of subject area experts, accessing their experience to explore issues such as unmet needs or to discuss future therapeutic strategies. When managed appropriately advisory boards generate powerful outcomes. Pharmaceutical companies derive several strategic and operational benefits from engaging with advisory boards, which consist of experts, often including physicians, researchers, and key opinion leaders (KOLs). We recently summarised the best way to achieve the most out of your advisory board in an issue of our Insider's Insights [1] (and stay within relevant regulations [2] [3]). Here are some key advantages summarised:
Expert Insights and Clinical Guidance
Early Feedback on Product Development
Influence and Credibility with Stakeholders
Access to Real-World Data and Patient Insights
Commercial Strategy and Market Access
Long-Term Relationship Building with KOLs
Risk Mitigation
Advisory boards are essential for providing expert insights, enhancing product development, building market credibility, and shaping commercialisation strategies, all while mitigating risks and improving patient outcomes. Their input drives informed decision-making and supports a pharmaceutical company’s efforts to bring innovative and effective therapies to market. Advisory boards should not be viewed as a stand-alone event, nor will they necessarily address all aspects of a knowledge gap. However, they can serve as a useful initiative that form part of the wider research efforts. They offer an opportune way to initiate discussion within a scientific field, and this momentum can have a hugely positive impact. Consider how the advisory board may contribute to an ongoing area of research and how to publish the discussion narrative and consensus in a scientific journal. If you publish the proceedings, you may not only want your attendees to be report authors but also be willing advocates actively involved in dissemination of its key messages.
References
Finding the best vehicle in which to publish your research findings is a perennial challenge.
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
Searching the literature can take various forms, ranging from a quick scan of recent publications
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
Scientific knowledge should be accessible to all and if you are those communicating science
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
Since 2013 we have been sharing our understanding on key issues with friends and clients via our Insider’s Insights.
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
We all need heroes - people who can champion our cause - helping the world to understand our rationale
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
Did you miss our Insider's Insight into understanding the complex world of bibliometrics [1]?
We recently encouraged writers (of all kinds) in our recent Insider’s Insight to experiment with large language.
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
